- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04601909
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
A Phase 1b, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Age-Related Sensorineural Hearing Loss
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 1b placebo-controlled, double-blind, randomized, single-dose safety study of intratympanic FX-322 dosed in subjects with age-related sensorineural hearing loss.
Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive one dose FX-322 (24) or placebo (6) and will return for safety, otologic, and audiologic assessments at Days 30 and 90 after the study injection.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 00000
- Clinical Trial Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 00000
- Clinical Trial Site
-
-
New York
-
Amherst, New York, United States, 00000
- Clinical Trial Site
-
-
Texas
-
San Antonio, Texas, United States, 00000
- Clinical Trial Site
-
-
Virginia
-
Norfolk, Virginia, United States, 00000
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure.
- Adult aged 66-85 years inclusive.
- Documented medical history consistent with age-related sensorineural hearing loss (documented audiogram at least 6 months prior to screening required).
- A pure tone average of 26-70 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz at Screening in the ear to be injected.
- Ability to communicate well with the Investigator and is willing to comply with and complete all the study procedures.
Exclusion Criteria:
- Subject has previously participated in a FX-322 clinical trial.
- Any subject with a flat audiogram between 500Hz and 8000Hz at Screening in the study ear. The difference in the range of threshold values across frequencies is ≤15 dB for the definition of a flat audiogram.
- Clinically significant abnormalities on safety laboratory tests.
- Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.
- Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening visit or on the prior audiogram (if the Investigator feels there is not a true conductive hearing loss, the Medical Monitor should be consulted).
- Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.
- Subject has had an intratympanic injection in either ear within 3 months of the screening visit.
- History of clinically significant vestibular symptoms at the discretion of the investigator. For example, BPPV may be considered acceptable whereas Meniere's would not.
- History of clinically significant systemic autoimmune disease (e.g. rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).
- Exposure to another investigational drug within 28 days prior to injection of study drug.
- Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).
Females of childbearing potential (those who are not surgically sterilized or post-menopausal) may not participate in the study if any of the following conditions exist:
- Pregnant or intend to become pregnant
- Nursing (lactating)
- Does not agree to use adequate birth control methods for the duration of the study (adequate birth control methods are: hormonal- oral, implantable, transdermal or injectable contraceptives; mechanical- spermicide in conjunction with a barrier such as a condom or diaphragm, IUD, or surgical sterilization of a partner.
NOTE: all female subjects of childbearing potential must consent to a urine pregnancy test as described in the Schedule of Assessments
- Any known factor, condition, or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results (e.g. previous high-dose aminoglycoside treatment).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: FX-322
FX-322, 1 dose (N=24)
|
active comparator
|
Placebo Comparator: Placebo
Placebo, 1 dose (n=6)
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systemic Safety: Number of patients with treatment-related adverse events
Time Frame: 3 months
|
Number of patients with treatment-related adverse events assessed by CTCAE v5.0
|
3 months
|
Local Safety: Number of patients with abnormal changes from baseline in otoscopic examinations
Time Frame: 3 months
|
Microscopic otoscopy will be included to specifically record any abnormalities of the external ear canal, tympanic membrane and middle ear.
|
3 months
|
Local Safety: The number of patients with abnormal changes from baseline in tympanometry
Time Frame: 3 months
|
Tympanometry tests the integrity of the tympanic membrane by varying air pressure in the ear canal.
Middle ear compliance (mL), peak pressure (daPa), and ear canal volume (mL) will be recorded.
|
3 months
|
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: 3 months
|
Risk assessment through a series of simple, plain-language questions
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Audiologic Response Endpoints: Speech Intelligibility - Word Recognition in Quiet (WR)
Time Frame: 3 months
|
Assessment of speech intelligibility using the Word Recognition in Quiet test measured with Consonant-Nucleus-Consonant (CNC) word lists.
|
3 months
|
Audiologic Response Endpoints: Speech Intelligibility - Words-In-Noise (WIN)
Time Frame: 3 months
|
Speech intelligibility using the Words-in-Noise test measured with Consonant-Nucleus-Consonant (CNC) word lists
|
3 months
|
Standard Pure Tone Audiometry
Time Frame: 3 months
|
Standard pure tone audiometry will be measured to determine a subject's threshold for hearing at standard frequencies (Hz)
|
3 months
|
Extended High Frequency Pure Tone Audiometry
Time Frame: 3 months
|
Pure tone audiometry will be measured to determine a subject's threshold for hearing at extended high range frequencies (Hz)
|
3 months
|
Tinnitus Assessment
Time Frame: 3 months
|
Measured by the Tinnitus Functional Index (TFI), with a scale ranging from 0 to 100 that defines severity categories based on 25 self-reported answers.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Carl LeBel, PhD, Frequency Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FX-322-112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss, Sensorineural
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
CochlearCompletedUnilateral Mixed Conductive and Sensorineural Hearing Loss (Diagnosis) | Sensorineural Hearing Loss, Unilateral With Normal Hearing on the Contralateral SideCanada
-
University College, LondonUnknownSensorineural Hearing Loss | Sensory Hearing Loss | Sensorineural Hearing Loss in Left Ear | Sensorineural Hearing Loss in Right Ear | Sensorineural HearingUnited Kingdom
-
Fundación Pública Andaluza para la gestión de la...RecruitingBilateral Sensorineural Hearing Loss | Unilateral Sensorineural Hearing LossSpain
-
University Hospital, AntwerpCochlearRecruitingHearing Loss, Unilateral | Cochlear Implants | Hearing Loss, Sensorineural, Severe | Hearing Loss, Sensorineural, Bilateral | Hearing Loss, Sensorineural, ProfoundBelgium
-
Auris Medical, Inc.TerminatedHearing Loss, Idiopathic Sudden SensorineuralUnited States, Korea, Republic of, Canada
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Cochlear Bone Anchored SolutionsCompletedSingle Sided Sensorineural Deafness | Mixed Hearing Loss, UnilateralDenmark, Spain, United Kingdom, Belgium
-
University of Colorado, DenverCompletedSudden Sensorineural Hearing Loss (SSNHL)United States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States